Emylcamate (marketed as Striatran by Merck) is an anxiolytic and muscle relaxant. It was patented in the US in 1961 (US Patent 2,972,564) and advertised for the treatment of anxiety and tension. It was claimed to be superior to meprobamate, which would eventually replace emylcamate.
Emylcamate (marketed as Striatran by Merck) is an anxiolytic and muscle relaxant. It was patented in the US in 1961 (US Patent 2,972,564) and advertised for the treatment of anxiety and tension. It was claimed to be superior to meprobamate, which would eventually replace emylcamate.
A study of the drug's effects in mice was done in 1959. It concluded that at 50 mg/kg emylcamate gave a 63% decrease in motor activity compared with meprobamate's 32% decrease, a doubling in effective potency. The therapeutic index in mice was also established: {| class="wikitable" |- ! Meprobamate !! Emylcamate !! Effect |- | 175 || 123 || ED50 (mg/kg) |- | 600 || 550|| LD50 (mg/kg) |- | 3.4 || 4.4|| Therapeutic index |}
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).